High-risk diabetic patients who underwent carotid stenting had fewer heart attacks and fewer major adverse events overall at one-year follow-up than those who underwent carotid endarterectomy surgery to prevent stroke, according to a study presented at the Society of Interventional Radiology meeting in Phoenix.
The data was collected from the high-risk diabetic arm of the Sapphire trial, a prospective, multi-center, randomized controlled trial at 29 U.S. centers. The trial compared the safety and efficacy of carotid stenting with embolic protection to standard carotid surgery to treat blocked carotid arteries to prevent stroke.
The stenting group had a 2.4% incidence of heart attacks compared with an 18.2% incidence in the surgical group. Incidence of major bleeding was 4.8% for the stenting group compared with 20.5% for the surgery group. The one-year major adverse event rate was 4.8% for stenting versus 25% for surgery.
The Sapphire trial utilized the Precise stent with an Angioguard filter manufactured by interventional technology developer Cordis Endovascular, a Johnson & Johnson subsidiary, which sponsored the study.
By AuntMinnie.com staff writersMarch 25, 2004
Related Reading
Guidant, Johnson & Johnson ink stent deal, February 27, 2004
Cordis stent gets FDA OK, September 5, 2003
Cordis files suit against Boston Scientific, January 15, 2003
Cordis debuts new biliary stent, August 27, 2002
Copyright © 2004 AuntMinnie.com
